Northern Trust Corp Graphite Bio, Inc. Transaction History

Northern Trust Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.24 - $2.66 $75,651 - $89,836	33,773 Added 13.76%	279,194 $731,000
Q3 2023 Nov 13, 2023	SELL	$2.18 - $2.77 $12,024 - $15,279	-5,516 Reduced 2.2%	245,421 $608,000
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.38 $439,032 - $600,781	177,746 Added 242.85%	250,937 $652,000
Q1 2023 May 15, 2023	SELL	$1.85 - $3.21 $10,254 - $17,793	-5,543 Reduced 7.04%	73,191 $179,000
Q4 2022 Feb 13, 2023	BUY	$2.82 - $3.59 $44,104 - $56,147	15,640 Added 24.79%	78,734 $261,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $40,977 - $61,611	14,531 Added 29.92%	63,094 $200,000
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $424,047 - $1.04 Million	-198,153 Reduced 80.32%	48,563 $134,000
Q1 2022 May 13, 2022	BUY	$5.1 - $13.06 $414,635 - $1.06 Million	81,301 Added 49.15%	246,716 $1.26 Million
Q4 2021 Feb 08, 2022	BUY	$8.41 - $16.71 $186,836 - $371,229	22,216 Added 15.51%	165,415 $2.06 Million
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $2.26 Million - $4.07 Million	143,199 New	143,199 $2.35 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.